|
Aptamer Group PLC on Wednesday announced the launch of its new biomarker discovery service, which utilises its proprietary Optimer technology to identify various indicators of health. The York, England-based synthetic binders developer said the launch created ‘a new fee-for-service revenue stream targeting the $62.4 billion global biomarker discovery market’. In response, shares in Aptamer were up 13% at 0.94 pence in London on Wednesday afternoon. The stock has more than tripled from 0.26p over the past year. The new service represents a shift away from current time-intensive methods, instead using the company’s Optimer technology in combination with advanced proteomic analysis to quickly identify disease-specific biomarkers at the molecular level. Aptamer said the identification of biomarkers was a ‘key drive of innovation in healthcare, particularly in areas of high unmet medical need’. The company expects the new service to be revenue-enhancing in the current financial year, providing opportunities for ‘immediate monetisation’ with ‘minimal’ investment needed upfront. The service will also allow pharmaceutical and biotechnology companies to accelerate their research & development pipelines without the need for ‘significant’ expenditure, Aptamer added. It is ‘well-positioned to capture significant demand’ from developers in the pharmaceutical, biotech and diagnostic sectors, with early interest already received. ‘This new service builds on our core strength in applying Optimer libraries to bind precisely to disease-relevant targets. Following our successful identification and validation of the biomarker for our fibrotic liver delivery system, we have seen strong interest from pharmaceutical and biotechnology companies seeking novel drug targets to strengthen their intellectual property positions,’ said Chief Executive Officer Arron Tolley. ‘Our approach enables the discovery of functional biomarkers in a fraction of the time required by traditional methods, which often take years of screening. With two additional biomarker discovery projects already progressing in the lab, we are excited to support our partners in accelerating the development of new treatments and diagnostics, while expanding the commercial impact of our Optimer platform.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
